PCRX News and Press, Pacira BioSciences Inc. From 11/03/22

Pacira BioSciences ( NASDAQ: PCRX ) posted wider-than-expected quarterly loss, as costs increased. Revenue rose 31.1% Y/Y to $167.5M in-line with estimates. Q3 GAAP EPS of -$0.02 misses by $0.39. Non-GAAP net income was $29.9 million, or $0.64 per share in the thir...

Pacira BioSciences, Inc. (PCRX) Q3 2022 Earnings Conference Call November 03, 2022 08:30 AM ET Company Participants Susan Mesco - Head, Investor Relations Dave Stack - Chairman & Chief Executive Officer Roy Winston - Chief Medical Officer Charlie Reinhart...

Pacira BioSciences press release ( NASDAQ: PCRX ): Q3 GAAP EPS of -$0.02 misses by $0.39 . Revenue of $167.5M (+31.1% Y/Y) in-line. Adjusted EBITDA of $55.2M in the third quarter of 2022, compared to $48.1M in the third quarter of 2021. Pacira ended the third q...

-- Third quarter revenue of $167 million , increased 31% over prior year -- -- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-...

Pacira BioSciences ( NASDAQ: PCRX ) is scheduled to announce Q3 earnings results on Thursday, November 3rd, before market open. The consensus EPS Estimate is $0.76 (+5.6% Y/Y) and the consensus Revenue Estimate is $167.53M (+31.2% Y/Y). Over the last 2 years, PCRX ha...

Summary Baillie Gifford’s 13F portfolio value decreased from ~$97.51B to ~$96.99B this quarter. They increased Shopify, Roblox, Zoom Video, and Twilio while reducing Albemarle Corporation and Li Auto ADR. The top three positions are Tesla Motors, Moderna, and MercadoLib...

Summary Exparel continues to face headwinds in the near term but should continue to grow in the following years. Zilretta has not done well since last year's acquisition, but there are objective issues that Pacira is working to address and growth should resume in the following qua...

TAMPA, Fla., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday, November 3, 2022. Following the release, the company will host a live conference cal...

Pacira BioSciences ( NASDAQ: PCRX ) has reported prelim Q3 revenues of $167.5M, up 31% year-over-year but below consensus estimate of $171.37M. EXPAREL sales were up around 9% Y/Y in the quarter to $132.6M. In Sep 2022, EXPAREL generated $45M in sales vs. $39.7M in Sep...

TAMPA, Fla., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited revenues of $167.5 million for the third quarter of 2022, compa...